Jenburkt Pharmaceuticals Limited (BOM:524731)
1,034.40
-5.65 (-0.54%)
At close: Sep 4, 2026
Jenburkt Pharmaceuticals Revenue
Jenburkt Pharmaceuticals had revenue of 355.12M INR in the quarter ending June 30, 2026, a decrease of -0.04%. This brings the company's revenue in the last twelve months to 1.69B, up 9.08% year-over-year. In the fiscal year ending March 31, 2026, Jenburkt Pharmaceuticals had annual revenue of 1.69B with 11.24% growth.
Revenue (ttm)
1.69B
Revenue Growth
+9.08%
P/S Ratio
2.71
Revenue / Employee
2.11M
Employees
801
Market Cap
4.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.69B | 170.49M | 11.24% |
| Mar 31, 2025 | 1.52B | 97.25M | 6.85% |
| Mar 31, 2024 | 1.42B | 52.17M | 3.82% |
| Mar 31, 2023 | 1.37B | 127.69M | 10.30% |
| Mar 31, 2022 | 1.24B | 146.86M | 13.44% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ZIM Laboratories | 3.97B |
| Albert David | 3.64B |
| Medico Remedies | 2.38B |
| Kilitch Drugs (India) | 2.37B |
| Medicamen Biotech | 2.06B |
| Ambalal Sarabhai Enterprises | 2.06B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
Jenburkt Pharmaceuticals News
- 4 weeks ago - Jenburkt Pharmaceuticals Quarterly report: Q1 2027 - Filings
- 4 months ago - Jenburkt Pharmaceuticals Quarterly report: Q4 2026 - Filings
- 4 months ago - Jenburkt Pharmaceuticals Annual report: Q4 2026 - Filings
- 7 months ago - Jenburkt Pharmaceuticals Quarterly report: Q3 2026 - Filings
- 10 months ago - Jenburkt Pharmaceuticals Quarterly report: Q2 2026 - Filings